Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation.
Dilated cardiomyopathy
Exercise
Heart failure
Muscle contraction
Skeletal myopathy
Journal
Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193
Informations de publication
Date de publication:
24 01 2019
24 01 2019
Historique:
received:
09
10
2018
accepted:
10
01
2019
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
2
7
2019
Statut:
epublish
Résumé
Skeletal muscle myopathy and exercise intolerance are diagnostic hallmarks of heart failure (HF). However, the molecular adaptations of skeletal muscles during dilated cardiomyopathy (DCM)-mediated HF are not completely understood. Skeletal muscle structure and function were compared in wild-type (WT) and cardiac myosin binding protein-C null mice (t/t), which develop DCM-induced HF. Cardiac function was examined by echocardiography. Exercise tolerance was measured using a graded maximum treadmill running test. Hindlimb muscle function was assessed in vivo from measurements of plantar flexor strength. Inflammatory status was evaluated from the expression of inflammatory markers and the presence of specific immune cell types in gastrocnemius muscles. Muscle regenerative capacityat days 3, 7, and 14 after eccentric contraction-induced injury was determined from the number of phenotypically new and adult fibers in the gastrocnemius, and functional recovery of plantar flexion torque. t/t mice developed DCM-induced HF in association with profound exercise intolerance, consistent with previous reports. Compared to WT, t/t mouse hearts show significant hypertrophy of the atria and ventricles and reduced fractional shortening, both systolic and diastolic. In parallel, the skeletal muscles of t/t mice exhibit weakness and myopathy. Compared to WT, plantar flexor muscles of t/t null mice produce less peak isometric plantar torque (Po), develop torque more slowly (+ dF/dt), and relax more slowly (- dF/dt, longer half-relaxation times,1/2RT). Gastrocnemius muscles of t/t mice have a greater number of fibers with smaller diameters and central nuclei. Oxidative fibers, both type I and type IIa, show significantly smaller cross-sectional areas and more central nuclei. These fiber phenotypes suggest ongoing repair and regeneration under homeostatic conditions. In addition, the ability of muscles to recover and regenerate after acute injury is impaired in t/t mice. Our studies concluded that DCM-induced HF induces a unique skeletal myopathy characterized by decreased muscle strength, atrophy of oxidative fiber types, ongoing inflammation and damage under homeostasis, and impaired regeneration after acute muscle injury. Furthermore, this unique myopathy in DCM-induced HF likely contributes to and exacerbates exercise intolerance. Therefore, efforts to develop therapeutic interventions to treat skeletal myopathy during DCM-induced HF should be considered.
Sections du résumé
BACKGROUND
Skeletal muscle myopathy and exercise intolerance are diagnostic hallmarks of heart failure (HF). However, the molecular adaptations of skeletal muscles during dilated cardiomyopathy (DCM)-mediated HF are not completely understood.
METHODS
Skeletal muscle structure and function were compared in wild-type (WT) and cardiac myosin binding protein-C null mice (t/t), which develop DCM-induced HF. Cardiac function was examined by echocardiography. Exercise tolerance was measured using a graded maximum treadmill running test. Hindlimb muscle function was assessed in vivo from measurements of plantar flexor strength. Inflammatory status was evaluated from the expression of inflammatory markers and the presence of specific immune cell types in gastrocnemius muscles. Muscle regenerative capacityat days 3, 7, and 14 after eccentric contraction-induced injury was determined from the number of phenotypically new and adult fibers in the gastrocnemius, and functional recovery of plantar flexion torque.
RESULTS
t/t mice developed DCM-induced HF in association with profound exercise intolerance, consistent with previous reports. Compared to WT, t/t mouse hearts show significant hypertrophy of the atria and ventricles and reduced fractional shortening, both systolic and diastolic. In parallel, the skeletal muscles of t/t mice exhibit weakness and myopathy. Compared to WT, plantar flexor muscles of t/t null mice produce less peak isometric plantar torque (Po), develop torque more slowly (+ dF/dt), and relax more slowly (- dF/dt, longer half-relaxation times,1/2RT). Gastrocnemius muscles of t/t mice have a greater number of fibers with smaller diameters and central nuclei. Oxidative fibers, both type I and type IIa, show significantly smaller cross-sectional areas and more central nuclei. These fiber phenotypes suggest ongoing repair and regeneration under homeostatic conditions. In addition, the ability of muscles to recover and regenerate after acute injury is impaired in t/t mice.
CONCLUSIONS
Our studies concluded that DCM-induced HF induces a unique skeletal myopathy characterized by decreased muscle strength, atrophy of oxidative fiber types, ongoing inflammation and damage under homeostasis, and impaired regeneration after acute muscle injury. Furthermore, this unique myopathy in DCM-induced HF likely contributes to and exacerbates exercise intolerance. Therefore, efforts to develop therapeutic interventions to treat skeletal myopathy during DCM-induced HF should be considered.
Identifiants
pubmed: 30678732
doi: 10.1186/s13395-019-0189-y
pii: 10.1186/s13395-019-0189-y
pmc: PMC6345027
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Subventions
Organisme : NHLBI NIH HHS
ID : RO1/R56 HL139680
Pays : United States
Organisme : NIH HHS
ID : RO1AM063710
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130356
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105826
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR067279
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR068286
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR063710
Pays : United States
Références
J Clin Invest. 1991 Dec;88(6):2077-82
pubmed: 1752965
Circ Res. 2017 Sep 15;121(7):749-770
pubmed: 28912181
Neuromuscul Disord. 2004 Apr;14(4):265-73
pubmed: 15019705
Circulation. 2010 Jan 26;121(3):419-25
pubmed: 20065166
Am J Physiol Heart Circ Physiol. 2014 Mar;306(6):H807-15
pubmed: 24464755
J Physiol. 2007 Jan 1;578(Pt 1):327-36
pubmed: 17038433
Circulation. 2001 Apr 24;103(16):2055-9
pubmed: 11319194
Stem Cells. 2013 Feb;31(2):384-96
pubmed: 23169615
Expert Opin Orphan Drugs. 2015;3(8):869-876
pubmed: 27547593
Circulation. 2006 Jul 11;114(2):126-34
pubmed: 16818813
Lancet. 1997 Apr 12;349(9058):1050-3
pubmed: 9107242
FEBS J. 2018 Jun;285(11):1973-1984
pubmed: 29473995
J Appl Physiol (1985). 2005 Dec;99(6):2189-95
pubmed: 16051711
J Appl Physiol (1985). 2008 Apr;104(4):952-7
pubmed: 18202167
Circ Heart Fail. 2009 Nov;2(6):700-6
pubmed: 19919996
Eur J Cell Biol. 1997 Dec;74(4):391-8
pubmed: 9438136
J Physiol. 2013 Jan 15;591(2):559-70
pubmed: 23109110
Lancet. 2017 Jul 22;390(10092):400-414
pubmed: 28190577
Exp Physiol. 2014 Apr;99(4):609-15
pubmed: 24293507
J Am Coll Cardiol. 1989 Nov 15;14(6):1464-73
pubmed: 2809005
Am J Physiol Cell Physiol. 2007 May;292(5):C1660-71
pubmed: 17151142
FASEB J. 2002 Oct;16(12):1630-2
pubmed: 12207010
J Clin Invest. 1999 Dec;104(12):1771
pubmed: 10606631
Circulation. 2000 Oct 10;102(15):1847-53
pubmed: 11023942
Nat Med. 2015 Jul;21(7):786-94
pubmed: 26053624
Development. 2010 Aug;137(16):2643-52
pubmed: 20610486
Cell Mol Life Sci. 2015 Jan;72(1):153-64
pubmed: 24947322
Stem Cells. 2008 Apr;26(4):997-1008
pubmed: 18258721
Am J Physiol Cell Physiol. 2005 Nov;289(5):C1179-87
pubmed: 16079187
J Physiol. 2002 Apr 15;540(Pt 2):571-80
pubmed: 11956344
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):287-96
pubmed: 25081949
Int J Cardiol. 1988 Feb;18(2):187-95
pubmed: 2830194
J Mol Cell Cardiol. 2017 Jan;102:83-93
pubmed: 27955979
Circ Res. 2006 Jun 23;98(12):1514-9
pubmed: 16690878
Exp Neurol. 2016 Mar;277:275-282
pubmed: 26775178
Am J Physiol Cell Physiol. 2004 Dec;287(6):C1605-15
pubmed: 15282190
J Exp Med. 2007 May 14;204(5):1057-69
pubmed: 17485518
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E392-401
pubmed: 19470832